Heron Therapeutics’ ZYNRELEF (HTX-011) Receives the US FDA’s Approval for the Management of Postoperative Pain

May 14, 2021 Auto Bot approval, FDA, regulatory 0

Shots:

  • The US FDA approved Zynrelef (bupivacaine and meloxicam) extended-release solution for postsurgical analgesia in patients with soft tissue or periarticular instillation for 72 hrs after a bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty
  • The approval is based on data from the P-III studies assessing Zynrelef vs bupivacaine solution in 1000 patients which demonstrated superiority to bupivacaine solution & sustained postoperative pain relief for up to 72 hrs and decreased the need for opioids
  • Zynrelef is the 1st FDA-approved extended-release dual-acting local anesthetic and is approved in 31 EU countries. The company plans to launch Zynrelef in Jul 2021

Click here to­ read full press release/ article | Ref: PRNewswire | Image: BioSpace

The post Heron Therapeutics’ ZYNRELEF (HTX-011) Receives the US FDA’s Approval for the Management of Postoperative Pain first appeared on PharmaShots.